HCM
SRPT icon

Hodges Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Hodges Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15,000
Closed -$316K – 306
2014
Q3 		$316K Buy
15,000
+5,000
+50% +$113K 0.01% 233
2014
Q2 		$298K Hold
10,000
– – 0.01% 227
2014
Q1 		$240K Hold
10,000
– – 0.01% 222
2013
Q4 		$204K Buy
+10,000
New +$297K 0.01% 227

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Hodges Capital Management's SRPT Position: Q4 2014 in Review

Hodges Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2014, closing a stake of 15,000 shares — an estimated $316K sold.

Hodges Capital Management first reported a position in SRPT in Q4 2013 and held it in 4 quarters. The position peaked at $316K in Q3 2014. 120 funds tracked by Wall St. Rank hold SRPT as of Q4 2014.

  • Hodges Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Hodges Capital Management sold 15,000 Sarepta Therapeutics shares in Q4 2014, an estimated $316K.
  • Hodges Capital Management first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 4 quarters.
  • Hodges Capital Management's Sarepta Therapeutics position peaked at $316K in Q3 2014.
  • 120 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2014.

Based on Hodges Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.